Breast ER+/HER2- D8535C00001 – CAMBRIA-2

Description

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant  Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.

Interested in this trial? Email [email protected].